James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 65,000 shares at $32.46 ($2.1M) on 2023-03-16, disclosed to the SEC on 2023-03-24.
Open-market sale of $2.1M AMLX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.86 | 30,796 | $981K | 47.3% |
| 2 | $31.86 | 30,796 | $981K | 47.3% |
| 3 | $32.46 | 1,704 | $55K | 2.7% |
| 4 | $32.46 | 1,704 | $55K | 2.7% |
| Total | $31.89 avg | 65,000 | $2.1M | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |